Skip to content

Clinical study on chewable tablets in smokers.

Clinical study to evaluate efficacy and safety of Smotect Azaadi chewable tablets for its effect on nicotine de-addition in smokers - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/01/079754
Enrollment
30
Registered
2025-01-29
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Project Happiness Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects smoking 5 to 10 cigarettes daily for more than 5 years 2. Subjects not suffering from any significant illness (medical or surgical) 3. Subjects of female gender or non-pregnant, non-lactating females. A urine pregnancy test is required for all female subjects of childbearing potential unless female subject has had a hysterectomy, tubal ligation, or is greater than or equal to 2 years postmenopausal. 4. Subjects willing to follow the procedures as per the study protocol and voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Known cases of Severe or Chronic disease. 2. Known subject of any active malignancy. 3. Subjects giving history of significant cardiovascular event less than or equal to 12 weeks prior to randomization. 4. Subjects having known chronic, contagious infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV. 5. Known subjects of having active metabolic or gastrointestinal diseases that may interfere with nutrient absorption, metabolism, or excretion, excluding diabetes. 6. Subjects with uncontrolled Diabetes and Hypertension. 7. Subjects using any other investigational drug within 1 month prior to recruitment. 8. Known hypersensitivity to any of the ingredients used in study drug. 9. Pregnant and Lactating females. 10. Subjects currently participating in any other Clinical study. 11. Any other condition due to which patients are deemed to be unsuitable by the investigator for reason(s) not specifically started in the exclusion criteria

Design outcomes

Primary

MeasureTime frame
Change in nicotine addiction (Smoking), average number of cigarettes smoked between study visits and number of days required for reduction or complete cessationTimepoint: Screening visit (Day -3), Baseline visit (Day 0), Visit 1 (day 15), and Visit 2 (Day 30)

Secondary

MeasureTime frame
1.Assessment of quality of life (QOL) on WHO QOL BRIEF Questionnaire 2. Assessment of level of Energy, level of stamina and physical strength on a 7- point scale 3. Assessment of level of stress using VAS 4. Assessment of change in daytime fatigue on VAS 5. Change in clinical symptoms related to smoking 6. Assessment of respiratory symptoms i.e. cough, sore throat etc associated with smoking 7. Change in Global evaluation for overall change on CGI-I Scale as per physician and subjects 8. Assessment of adverse events 9. Change in global assessment of overall safety of study dugs as per the physician and subjects Timepoint: Screening visit (Day -3), Baseline visit (Day 0), Visit 1 (day 15), and Visit 2 (Day 30)

Countries

India

Contacts

Public ContactDr Sanjay Tamoli

Target Institute of Medical Education and Research Pvt Ltd

targetinstitute@yahoo.com9322522252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026